Vericiguat is under clinical development by Bayer and currently in Phase II for Diastolic Heart Failure (HFpEF). According to GlobalData, Phase II drugs for Diastolic Heart Failure (HFpEF) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Vericiguat LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Vericiguat overview

Vericiguat (Verquvo, Verilutro, Verqalif) acts as a vasodilator agent and an antihypertensive agent. It is formulated as film-coated tablets for oral route of administration. It is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic heart failure and ejection fraction less than 45%.
Vericiguat (BAY-1021189) is under development for the treatment of heart failure due to systemic left ventricular systolic dysfunction (systolic heart failure), heart failure with preserved ejection fraction (HFpEF), metabolic syndrome, coronary vascular dysfunction, post-acute sequelae of COVID 2019 and chronic fatigue syndrome (myalgic encephalomyelitis). The drug candidate is administered orally. It targets soluble guanylyl cyclase (sGC). It was also under development for the treatment of coronary artery disease,

Bayer overview

Bayer carries out the discovery, development, manufacturing, and commercialization of products for human health, and agriculture. It provides medicines for cardiovascular diseases, women’s health, cancer, hematology, ophthalmology, and other indications. It also strives to develop new molecules and technologies for use in the fields of medicine and modern agriculture. The company’s product portfolio includes prescription products, specialty pharmaceuticals, diagnostic imaging equipment, non-prescription (over-the-counter or OTC) products, seeds, crop protection solutions and non-agricultural pest control solutions. Bayer markets its products through wholesalers, pharmacies, hospitals, and retailers. It operates through a network of subsidiaries in Asia-Pacific, Europe, North America, Latin America, Africa, and the Middle East. Bayer is headquartered in Leverkusen, North Rhine-Westphalia, Germany.

For a complete picture of Vericiguat’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.